New Data Prompt FDA Review Period Extension for Omecamtiv Mecarbil
The FDA extended the action date by 3 months to review additional pharmacokinetic analyses provided by the Company.
The FDA extended the action date by 3 months to review additional pharmacokinetic analyses provided by the Company.
Risk increased with intravenous vitamin C versus placebo for adults with sepsis in the ICU receiving vasopressor therapy
Those who are partially vaccinated and unvaccinated face same increased risk, while boosted and fully vaccinated adults fare best
The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.
Updates include effects in T2D patients of finerenone on CV outcomes in those with CKD; of SGLT2 inhibitors on heart failure, renal outcomes
Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility.
No reduction seen in first occurrence of nonfatal MI, stroke, or CV death with either metformin or lifestyle intervention versus placebo
Aspirin use among patients with chronic kidney disease was associated with reduced risk for major adverse cardiovascular events.
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare
Risk for stroke, MI, all-cause mortality similar for those initiating SGLT-2i or metformin